FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1764-1765 April 17, 2008 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Edited by George C. Prendergast and Elizabeth M. Jaffee. 409 pp., illustrated. San Diego, CA, Elsevier Academic Press, 2007. $99.95. ISBN 978-0-12-372551-6.

The successful manipulation of a cancer-directed immune response has long been a goal of cancer immunologists. Occasionally, spectacular successes have reinforced the enthusiasm of some investigators for this goal, but the more common failed attempts to manipulate the immune response have led many to conclude that other treatments will be more productive. These polarized views have been tempered by recent advances in the understanding of the elements and regulation of the immune response, and by the definition of how cancers evade immune recognition and disarm, divert, or destroy immune effector mechanisms. Many authorities believe that new treatment strategies that address . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.